What distinguishes this new #remdesivir trial in @TheLancet is that it was:
1. Peer-reviewed & professionally edited
2. Done by scientists w/o financial or other links to the drug's manufacturer, Gilead
3. Was "well conducted w/ high protocol adherence & no loss to followup"..
1. Peer-reviewed & professionally edited
2. Done by scientists w/o financial or other links to the drug's manufacturer, Gilead
3. Was "well conducted w/ high protocol adherence & no loss to followup"..
4. Accompanied by a commentary written by a leading statistical expert who calls for
5. "data sharing... allowing rapid curation of relevant datasets for individual patient data meta-analyses..."
and our "best way to obtain robust insights" on treatments for #COVID19 ...
5. "data sharing... allowing rapid curation of relevant datasets for individual patient data meta-analyses..."
and our "best way to obtain robust insights" on treatments for #COVID19 ...
6. Done with a proper comparison group of patients given standard treatment but no #remdesivir, allocated at random
7. Registered in the NIH registry ClinicalTrials.gov (NCT04257656)
8. Done with no protocol (or outcome) amendments or changes
7. Registered in the NIH registry ClinicalTrials.gov (NCT04257656)
8. Done with no protocol (or outcome) amendments or changes
